Poetker David M
Am J Rhinol Allergy. 2017 May 1;31(3):205-206. doi: 10.2500/ajra.2017.31.4427.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease that leads to frequent epistaxis. It can have a significant impact on quality of life. Many reports exist regarding various therapies to address the epistaxis.
We presented our technique for addressing the epistaxis associated with HHT.
Patients are treated in the operating room while they are under general anesthesia. A local anesthetic is injected sublabially, and oxymetazoline is dripped into the nose. The coblation wand is used to treat the telangiectasias. Bevacizumab is then injected into the nasal cavity bilaterally.
The coblation wand, with or without adjunctive bevacizumab injection, is a technically feasible intervention for patients with HHT that all providers can perform.
遗传性出血性毛细血管扩张症（HHT）是一种常染色体显性疾病，可导致频繁鼻出血，对生活质量有重大影响。关于治疗鼻出血的各种疗法已有许多报道。
我们介绍了治疗与HHT相关鼻出血的技术。
患者在全身麻醉下于手术室接受治疗。在唇下注射局部麻醉剂，并将羟甲唑啉滴入鼻腔。使用低温等离子体消融棒治疗毛细血管扩张症。然后双侧鼻腔注射贝伐单抗。
无论是否辅助注射贝伐单抗，低温等离子体消融棒对HHT患者来说是一种技术上可行的干预措施，所有医疗人员均可操作。
